As of May 22
| +0.02 / +0.58%|
The 6 analysts offering 12-month price forecasts for AcelRx Pharmaceuticals Inc have a median target of 5.50, with a high estimate of 14.00 and a low estimate of 3.00. The median estimate represents a +58.50% increase from the last price of 3.47.
The current consensus among 6 polled investment analysts is to Hold stock in AcelRx Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.